KAIYADRU

KAIYADRU is an early preclinical drug candidate being developed by Hoverink Biotechnologies. Publicly available information indicates it is the company's lead product candidate, with plans to pursue future clinical development in the United States and to file regulatory submissions including an IND with the FDA and an MAA. However, the active ingredient, modality, molecular target, mechanism of action, dosage form, route of administration, and specific therapeutic indication have not been publicly disclosed in the provided materials, so the asset is best characterized as an undisclosed pharmaceutical development program rather than a well-defined named active substance.

Brand names

KAIYADRU